Attention Deficit Hyperactivity Disorder
📧 Sign up to get email alerts when something new happens for Attention Deficit Hyperactivity Disorder.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2016-12-20Clinical Trial Update: Mental Health Services for Foster and Adopted Children [Phase 1]
Phase 1 clinical trial evaluating mental health services for foster and adopted children has completed. It addresses attention-deficit/hyper…
-
CLINICAL_TRIALS trial_result · 2016-12-16Clinical Trial Update: Comparing School Based Interventions for Adolescents With Attention Deficit Hyperactivity Disorder [Phase 2]
Phase 2 clinical trial update assessing school-based interventions for adolescents with attention-deficit/hyperactivity disorder.
-
CLINICAL_TRIALS trial_result · 2016-12-06Clinical Trial Update: Behavioral Effects of Obstructive Sleep Apnea in Children
A completed clinical trial examining the behavioral effects of obstructive sleep apnea in children, with potential links to ADHD-related beh…
-
FDA approval · 2016-11-30FDA Approved: CONCERTA — Supplemental Application (Janssen Pharmaceuticals, Inc.)
FDA approved a supplemental application for CONCERTA (methylphenidate hydrochloride) submitted by Janssen Pharmaceuticals, Inc. The action u…
-
FDA approval · 2016-11-30FDA Approved: GUANFACINE — Supplemental Application (Actavis Pharma, Inc.)
The FDA approved Actavis Pharma, Inc.'s supplemental application for guanfacine, enabling continued marketing of a generic product. This act…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2016-11-30Clinical Trial Update: Prevention of Stimulant-Induced Euphoria With an Opioid Receptor Antagonist [Phase 4]
Phase 4 clinical trial evaluated whether an opioid receptor antagonist could prevent stimulant-induced euphoria in individuals with ADHD. Th…
-
FDA approval · 2016-11-30FDA Approved: DEXMETHYLPHENIDATE HYDROCHLORIDE — Original Application (Par Health USA, LLC)
FDA approved an Original Application for dexmethylphenidate hydrochloride, a generic ADHD medication, manufactured by Par Health USA, LLC.
-
CLINICAL_TRIALS research · 2016-11-29Clinical Trial Update: Differences in Attentional Profile of Children Diagnosed With ADHD Versus Children Diagnosed With Other Mental Conditions
A clinical trial update examining differences in attentional profiles between children diagnosed with ADHD and those with other mental healt…
-
CLINICAL_TRIALS trial_result · 2016-11-25Clinical Trial Update: Effectiveness and Duration of Effect of Open Treatment in Attention Deficit Hyperactivity Disorder (ADHD) Patients Treated With Lisdexamfetamine Dimesylate(Vyvanse) [Phase 4]
A Phase 4 clinical trial reports on the effectiveness and duration of effect of open-label lisdexamfetamine dimesylate (Vyvanse) in patients…
-
CLINICAL_TRIALS trial_result · 2016-11-15Clinical Trial Update: Neurofeedback Study ADHD [Phase 2]
This document provides an update on a Phase 2 neurofeedback trial for ADHD.
-
CLINICAL_TRIALS trial_result · 2016-11-08Clinical Trial Update: Evaluation of an Intervention for Improving Community-based Pediatric Attention-Deficit Hyperactivity Disorder (ADHD) Care [Phase 4]
Phase 4 clinical trial update reporting the results of an intervention to improve community-based care for pediatric attention-deficit/hyper…
-
FDA approval · 2016-11-07FDA Approved: METHYLPHENIDATE HYDROCHLORIDE — Original Application (Rising Pharma Holdings, Inc.)
FDA approved the original application for methylphenidate hydrochloride from Rising Pharma Holdings, Inc., a generic stimulant indicated for…
-
CLINICAL_TRIALS research · 2016-11-01Clinical Trial Update: Methylphenidate in Adults With Attention Deficit/Hyperactivity Disorder [Phase 4]
A Phase 4 clinical trial evaluating methylphenidate in adults with attention-deficit/hyperactivity disorder is currently recruiting in Porto…
-
FDA approval · 2016-10-28FDA Approved: METHYLPHENIDATE HYDROCHLORIDE — Supplemental Application (SpecGx LLC)
FDA approved a supplemental application for a methylphenidate hydrochloride generic product manufactured by SpecGx LLC.
-
FDA approval · 2016-10-28FDA Approved: DEXTROAMPHETAMINE SACCHARATE AND AMPHETAMINE ASPARTATE AND DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE — Supplemental Application (SpecGx LLC)
FDA approved a supplemental application for a generic product containing dextroamphetamine saccharate, amphetamine aspartate, dextroamphetam…
-
FDA approval · 2016-10-28FDA Approved: METHYLPHENIDATE HYDROCHLORIDE EXTENDED-RELEASE — Supplemental Application (SpecGx LLC)
FDA approved a supplemental application for SpecGx LLC to market methylphenidate hydrochloride extended-release as a generic ADHD treatment.
-
FDA approval · 2016-10-28FDA Approved: DEXTROAMPHETAMINE SULFATE — Supplemental Application (SpecGx LLC)
FDA approved a supplemental application for dextroamphetamine sulfate by SpecGx LLC under an ANDA. This action confirms the approval of a ge…
-
FDA approval · 2016-10-28FDA Approved: METHYLPHENIDATE HYDROCHLORIDE EXTENDED-RELEASE — Supplemental Application (SpecGx LLC)
FDA approved a supplemental application for methylphenidate hydrochloride extended-release from SpecGx LLC.
-
CLINICAL_TRIALS trial_result · 2016-10-28Clinical Trial Update: Communication in Adolescents With ADHD
The clinical trial evaluating communication in adolescents with ADHD has completed.
-
CLINICAL_TRIALS trial_result · 2016-10-26Clinical Trial Update: An Evaluation of Neurofeedback Efficacy in Adults With ADHD [NA]
The trial completed an evaluation of neurofeedback as a treatment for adults with Attention-deficit/hyperactivity disorder.
-
CLINICAL_TRIALS trial_result · 2016-10-25Clinical Trial Update: Obesity Treatment Enhanced With Working Memory Training [NA]
The document reports completion of a clinical trial evaluating obesity treatment enhanced with working memory training. ADHD and obesity-rel…
-
CLINICAL_TRIALS trial_result · 2016-10-25Clinical Trial Update: The Feasibility of a Brief Attention Training Technique in Improving Behaviour and Attention in Children With ADHD [NA]
A completed clinical trial assessing the feasibility of a brief attention training technique to improve behavior and attention in children w…
-
FDA approval · 2016-10-25FDA Approved: DEXTROAMPHETAMINE SULFATE EXTENDED-RELEASE — Supplemental Application (SpecGx LLC)
The FDA approved a supplemental application from SpecGx LLC for dextroamphetamine sulfate extended-release, clearing a generic extended-rele…
-
FDA approval · 2016-10-14FDA Approved: VYVANSE — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
FDA approved a supplemental application for VYVANSE (lisdexamfetamine dimesylate) from Takeda Pharmaceuticals America, Inc.
-
CLINICAL_TRIALS research · 2016-10-11Clinical Trial Update: Intensive Executive Function Training [NA]
This clinical trial update concerns an intensive executive function training program for Attention Deficit Hyperactivity Disorder; the curre…